Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Novel use of peatlands as future locations for the sustainable intensification of freshwater aquaculture production - A case study from the Republic of Ireland.

O'Neill EA, Stejskal V, Clifford E, Rowan NJ.

Sci Total Environ. 2020 Mar 1;706:136044. doi: 10.1016/j.scitotenv.2019.136044. Epub 2019 Dec 10.

PMID:
31855652
2.

Novel use of the alga Pseudokirchneriella subcapitata, as an early-warning indicator to identify climate change ambiguity in aquatic environments using freshwater finfish farming as a case study.

O'Neill EA, Rowan NJ, Fogarty AM.

Sci Total Environ. 2019 Nov 20;692:209-218. doi: 10.1016/j.scitotenv.2019.07.243. Epub 2019 Jul 17.

PMID:
31344572
3.

Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study.

Frias JP, Zimmer Z, Lam RLH, Amorin G, Ntabadde C, Iredale C, O'Neill EA, Engel SS, Kaufman KD, Makimura H, Crutchlow MF.

Diabetes Obes Metab. 2019 May;21(5):1128-1135. doi: 10.1111/dom.13626. Epub 2019 Feb 17.

4.

Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.

Roussel R, Duran-García S, Zhang Y, Shah S, Darmiento C, Shankar RR, Golm GT, Lam RLH, O'Neill EA, Gantz I, Kaufman KD, Engel SS.

Diabetes Obes Metab. 2018 Nov 4. doi: 10.1111/dom.13574. [Epub ahead of print]

5.

Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with premixed insulin.

Yu M, Shankar RR, Zhang R, Zhang Y, Lin J, O'Neill EA, Chen G, Liu S, Tu Y, Engel SS.

Diabetes Obes Metab. 2019 Feb;21(2):408-411. doi: 10.1111/dom.13517. Epub 2018 Oct 3.

PMID:
30178570
6.

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study.

Scott R, Morgan J, Zimmer Z, Lam RLH, O'Neill EA, Kaufman KD, Engel SS, Raji A.

Diabetes Obes Metab. 2018 Dec;20(12):2876-2884. doi: 10.1111/dom.13473. Epub 2018 Aug 16.

7.

Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical Trials.

Raji A, Long J, Lam RLH, O'Neill EA, Engel SS.

Diabetes Ther. 2018 Aug;9(4):1581-1589. doi: 10.1007/s13300-018-0461-x. Epub 2018 Jun 23.

8.

Characteristics of Elderly Patients Initiating Sitagliptin or Non-DPP-4-Inhibitor Oral Antihyperglycemic Agents: Analysis of a Cross-Sectional US Claims Database.

Wang T, McNeill AM, Chen Y, O'Neill EA, Engel SS.

Diabetes Ther. 2018 Feb;9(1):309-315. doi: 10.1007/s13300-017-0360-6. Epub 2018 Jan 12.

9.

Body Image Assessment Among Community Mental Health Providers.

Ramseyer Winter V, Brett A, Pevehouse-Pfeiffer D, O'Neill EA, Ellis-Ordway N.

Community Ment Health J. 2018 Jul;54(5):600-606. doi: 10.1007/s10597-017-0194-8. Epub 2017 Nov 14.

PMID:
29138959
10.

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.

Lee SH, Gantz I, Round E, Latham M, O'Neill EA, Ceesay P, Suryawanshi S, Kaufman KD, Engel SS, Lai E.

BMC Endocr Disord. 2017 Nov 6;17(1):70. doi: 10.1186/s12902-017-0219-x.

11.

A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes.

Home P, Shankar RR, Gantz I, Iredale C, O'Neill EA, Jain L, Pong A, Suryawanshi S, Engel SS, Kaufman KD, Lai E.

Diabetes Res Clin Pract. 2018 Apr;138:253-261. doi: 10.1016/j.diabres.2017.10.018. Epub 2017 Oct 24.

12.

Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds.

Gantz I, Sokolova L, Jain L, Iredale C, O'Neill EA, Wei Z, Lam R, Suryawanshi S, Kaufman KD, Engel SS, Lai E.

Clin Ther. 2017 Oct;39(10):2024-2037. doi: 10.1016/j.clinthera.2017.08.009. Epub 2017 Sep 18.

13.

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.

Gantz I, Chen M, Suryawanshi S, Ntabadde C, Shah S, O'Neill EA, Engel SS, Kaufman KD, Lai E.

Cardiovasc Diabetol. 2017 Sep 11;16(1):112. doi: 10.1186/s12933-017-0593-8.

14.

A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control.

Gantz I, Okamoto T, Ito Y, Sato A, Okuyama K, O'Neill EA, Engel SS, Lai E; Omarigliptin Study 015 Group.

Diabetes Ther. 2017 Aug;8(4):793-810. doi: 10.1007/s13300-017-0270-7. Epub 2017 Jun 6.

15.

A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

Handelsman Y, Lauring B, Gantz I, Iredale C, O'Neill EA, Wei Z, Suryawanshi S, Kaufman KD, Engel SS, Lai E.

Curr Med Res Opin. 2017 Oct;33(10):1861-1868. doi: 10.1080/03007995.2017.1335638. Epub 2017 Jun 28.

PMID:
28548024
16.

A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes.

Gantz I, Okamoto T, Ito Y, Okuyama K, O'Neill EA, Kaufman KD, Engel SS, Lai E; the Omarigliptin Study 020 Group.

Diabetes Obes Metab. 2017 Nov;19(11):1602-1609. doi: 10.1111/dom.12988. Epub 2017 Jul 6.

17.

A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment.

Chacra A, Gantz I, Mendizabal G, Durlach L, O'Neill EA, Zimmer Z, Suryawanshi S, Engel SS, Lai E.

Int J Clin Pract. 2017 Jun;71(6). doi: 10.1111/ijcp.12955. Epub 2017 Apr 27.

18.

Exploring Relationships between Body Appreciation and Self-Reported Physical Health among Young Women.

Ramseyer Winter V, O'Neill EA, Omary A.

Health Soc Work. 2017 May 1;42(2):e62-e67. doi: 10.1093/hsw/hlx006.

PMID:
28339944
19.
20.

A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone.

Wang W, Ning G, Ma J, Liu X, Zheng S, Wu F, Xu L, O'Neill EA, Fujita KP, Engel SS, Kaufman KD, Shankar RR.

Curr Med Res Opin. 2017 Apr;33(4):693-699. doi: 10.1080/03007995.2016.1277200. Epub 2017 Jan 25.

PMID:
28035868
21.

Exploring body appreciation and women's health-related quality of life: The moderating role of age.

O'Neill EA, Ramseyer Winter V, Pevehouse D.

J Health Psychol. 2018 Dec;23(14):1810-1819. doi: 10.1177/1359105316675212. Epub 2016 Nov 1.

PMID:
27807257
22.

The Role of Diabetes in Predicting Employment Status for Individuals with Bipolar Disorder.

O'Neill EA.

Soc Work Public Health. 2016 Nov-Dec;31(7):646-655. Epub 2016 Jun 28.

PMID:
27351241
23.

Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus.

Ji L, Han P, Wang X, Liu J, Zheng S, Jou YM, O'Neill EA, Golm GT, Engel SS, Kaufman KD, Shankar RR.

J Diabetes Investig. 2016 Sep;7(5):727-36. doi: 10.1111/jdi.12511. Epub 2016 May 19.

24.

A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.

Moses RG, Round E, Shentu Y, Golm GT, O'neill EA, Gantz I, Engel SS, Kaufman KD, Goldstein BJ.

J Diabetes. 2016 Sep;8(5):701-11. doi: 10.1111/1753-0407.12351. Epub 2016 Feb 3.

PMID:
26625270
25.

Design, synthesis, and biological evaluation of aminopyrazine derivatives as inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).

Lin S, Malkani S, Lombardo M, Yang L, Mills SG, Chapman K, Thompson JE, Zhang WX, Wang R, Cubbon RM, O'Neill EA, Hale JJ.

Bioorg Med Chem Lett. 2015 Nov 15;25(22):5402-8. doi: 10.1016/j.bmcl.2015.09.016. Epub 2015 Sep 8.

PMID:
26403928
26.

Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes.

Katzeff HL, Williams-Herman D, Xu L, Golm GT, Wang H, Dong Q, Johnson JR, O'Neill EA, Kaufman KD, Engel SS, Goldstein BJ.

Curr Med Res Opin. 2015 Jun;31(6):1071-7. doi: 10.1185/03007995.2015.1037259.

PMID:
25850968
27.

Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.

Bays HE, Brinton EA, Triscari J, Chen E, Maccubbin D, MacLean AA, Gibson KL, Ruck RA, Johnson-Levonas AO, O'Neill EA, Mitchel YB.

Vasc Health Risk Manag. 2015 Feb 24;11:165-72. doi: 10.2147/VHRM.S70907. eCollection 2015.

28.

Erratum to: Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials.

Ommen ES, Xu L, O'Neill EA, Goldstein BJ, Kaufman KD, Engel SS.

Diabetes Ther. 2015 Mar;6(1):97-8. doi: 10.1007/s13300-015-0101-7. No abstract available.

29.

A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus.

Shankar RR, Xu L, Golm GT, O'Neill EA, Goldstein BJ, Kaufman KD, Engel SS.

Int J Clin Pract. 2015 Jun;69(6):626-31. doi: 10.1111/ijcp.12607. Epub 2015 Feb 4.

PMID:
25652751
30.

Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials.

Ommen ES, Xu L, O'Neill EA, Goldstein BJ, Kaufman KD, Engel SS.

Diabetes Ther. 2015 Mar;6(1):29-40. doi: 10.1007/s13300-015-0098-y. Epub 2015 Jan 30. Erratum in: Diabetes Ther. 2015 Mar;6(1):97-8.

31.

Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia.

Kaplan SA, Lee JY, O'Neill EA, Meehan AG, Kusek JW.

Aging Male. 2013 Dec;16(4):169-72. doi: 10.3109/13685538.2013.844786. Epub 2013 Oct 17.

PMID:
24134648
32.

Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.

Alba M, Ahrén B, Inzucchi SE, Guan Y, Mallick M, Xu L, O'Neill EA, Williams-Herman DE, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2013 Dec;15(12):1101-10. doi: 10.1111/dom.12145. Epub 2013 Jul 19.

PMID:
23782502
33.

Recent trends in the characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large U.S. claims database.

Brodovicz KG, Kou TD, Alexander CM, O'Neill EA, Senderak M, Engel SS, Girman CJ.

Int J Clin Pract. 2013 May;67(5):449-54. doi: 10.1111/ijcp.12090.

PMID:
23574104
34.

The effects of simvastatin on the pharmacokinectics of sitagliptin.

Cerra M, Luo WL, Li SX, Matthews C, O'Neill EA, Wagner JA, Stoch SA, Anderson MS.

J Popul Ther Clin Pharmacol. 2012;19(3):e356-60. Epub 2012 Oct 11.

PMID:
23077137
35.

Synthesis and biological activity of pyridopyridazin-6-one p38α MAP kinase inhibitors. Part 2.

Tynebor RM, Chen MH, Natarajan SR, O'Neill EA, Thompson JE, Fitzgerald CE, O'Keefe SJ, Doherty JB.

Bioorg Med Chem Lett. 2012 Sep 15;22(18):5979-83. doi: 10.1016/j.bmcl.2012.07.035. Epub 2012 Aug 2.

PMID:
22901390
36.

Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk.

Brodovicz KG, Kou TD, Alexander CM, O'Neill EA, Engel SS, Girman CJ, Goldstein BJ.

Diabetes Obes Metab. 2012 Dec;14(12):1123-8. doi: 10.1111/j.1463-1326.2012.01667.x. Epub 2012 Aug 14.

PMID:
22831166
37.

Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.

Yoon KH, Steinberg H, Teng R, Golm GT, Lee M, O'Neill EA, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2012 Aug;14(8):745-52. doi: 10.1111/j.1463-1326.2012.01594.x. Epub 2012 Apr 17.

PMID:
22405352
38.

Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.

Bays H, Giezek H, McKenney JM, O'Neill EA, Tershakovec AM.

Metab Syndr Relat Disord. 2012 Aug;10(4):260-6. doi: 10.1089/met.2012.0005. Epub 2012 Mar 8.

PMID:
22400810
39.

Reconstituted HDL elicits marked changes in plasma lipids following single-dose injection in C57Bl/6 mice.

Chen Z, O'Neill EA, Meurer RD, Gagen K, Luell S, Wang SP, Ichetovkin M, Frantz-Wattley B, Eveland S, Strack AM, Fisher TS, Johns DG, Sparrow CP, Wright SD, Hubbard BK, Carballo-Jane E.

J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):315-23. doi: 10.1177/1074248411426144. Epub 2011 Nov 8.

PMID:
22067613
40.

Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.

Wainstein J, Katz L, Engel SS, Xu L, Golm GT, Hussain S, O'Neill EA, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2012 May;14(5):409-18. doi: 10.1111/j.1463-1326.2011.01530.x. Epub 2011 Dec 22.

PMID:
22059736
41.

Metabolic syndrome in mice induced by expressing a transcriptional activator in adipose tissue.

Zhang L, Zhou Y, Zhu AY, Li XQ, Mundt SS, Gao L, Lisnock J, Hernandez M, Alonso-Galicia M, Springer MS, O'Neill EA, Daugherty BL, Puig O.

Transgenic Res. 2012 Jun;21(3):633-44. doi: 10.1007/s11248-011-9562-2. Epub 2011 Oct 26.

PMID:
22038448
42.

Risk of acute renal failure in patients with Type 2 diabetes mellitus.

Girman CJ, Kou TD, Brodovicz K, Alexander CM, O'Neill EA, Engel S, Williams-Herman DE, Katz L.

Diabet Med. 2012 May;29(5):614-21. doi: 10.1111/j.1464-5491.2011.03498.x.

PMID:
22017349
43.

A gene expression signature that classifies human atherosclerotic plaque by relative inflammation status.

Puig O, Yuan J, Stepaniants S, Zieba R, Zycband E, Morris M, Coulter S, Yu X, Menke J, Woods J, Chen F, Ramey DR, He X, O'Neill EA, Hailman E, Johns DG, Hubbard BK, Yee Lum P, Wright SD, Desouza MM, Plump A, Reiser V.

Circ Cardiovasc Genet. 2011 Dec;4(6):595-604. doi: 10.1161/CIRCGENETICS.111.960773. Epub 2011 Oct 18.

PMID:
22010137
44.

A randomized clinical trial comparing point-of-care platelet function assays and bleeding time in healthy subjects treated with aspirin or clopidogrel.

Chen F, Maridakis V, O'neill EA, Beals C, Radziszewski W, de Lepeleire I, Van Dyck K, Depré M, Bolognese JA, de Hoon J, Jacquemin M.

Platelets. 2012;23(4):249-58. doi: 10.3109/09537104.2011.604806. Epub 2011 Sep 15.

PMID:
21919555
45.

High-throughput simultaneous analysis of RNA, protein, and lipid biomarkers in heterogeneous tissue samples.

Reiser V, Smith RC, Xue J, Kurtz MM, Liu R, Legrand C, He X, Yu X, Wong P, Hinchcliffe JS, Tanen MR, Lazar G, Zieba R, Ichetovkin M, Chen Z, O'Neill EA, Tanaka WK, Marton MJ, Liao J, Morris M, Hailman E, Tokiwa GY, Plump AS.

Clin Chem. 2011 Nov;57(11):1545-55. doi: 10.1373/clinchem.2010.157743. Epub 2011 Sep 13.

46.

The effects of simvastatin treatment on plasma lipid-related biomarkers in men with dyslipidaemia.

Chen F, Maridakis V, O'Neill EA, Hubbard BK, Strack A, Beals C, Herman GA, Wong P.

Biomarkers. 2011 Jun;16(4):321-33. doi: 10.3109/1354750X.2011.561367. Epub 2011 Mar 21.

PMID:
21417623
47.

Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.

Arechavaleta R, Seck T, Chen Y, Krobot KJ, O'Neill EA, Duran L, Kaufman KD, Williams-Herman D, Goldstein BJ.

Diabetes Obes Metab. 2011 Feb;13(2):160-8. doi: 10.1111/j.1463-1326.2010.01334.x.

PMID:
21199268
48.

Synthesis and biological activity of pyridopyridazin-6-one p38 MAP kinase inhibitors. Part 1.

Tynebor RM, Chen MH, Natarajan SR, O'Neill EA, Thompson JE, Fitzgerald CE, O'Keefe SJ, Doherty JB.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):411-6. doi: 10.1016/j.bmcl.2010.10.128. Epub 2010 Oct 30.

PMID:
21084192
49.

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes.

Girman CJ, Kou TD, Cai B, Alexander CM, O'Neill EA, Williams-Herman DE, Katz L.

Diabetes Obes Metab. 2010 Sep;12(9):766-71. doi: 10.1111/j.1463-1326.2010.01231.x.

PMID:
20649628
50.

Biochemical characterization of cholesteryl ester transfer protein inhibitors.

Ranalletta M, Bierilo KK, Chen Y, Milot D, Chen Q, Tung E, Houde C, Elowe NH, Garcia-Calvo M, Porter G, Eveland S, Frantz-Wattley B, Kavana M, Addona G, Sinclair P, Sparrow C, O'Neill EA, Koblan KS, Sitlani A, Hubbard B, Fisher TS.

J Lipid Res. 2010 Sep;51(9):2739-52. doi: 10.1194/jlr.M007468. Epub 2010 May 10.

Supplemental Content

Loading ...
Support Center